CE-158

CE-158 is an atypical dopamine reuptake inhibitor (DRI) that was derived from modafinil.^{[1][2][3][4][5]} It is often but not always referred to as the enantiopure enantiomer (S,S)-CE-158 instead.^[2][3][5]

CE-158

Clinical data
Other names	(S,S)-CE-158; S,S-CE-158
Drug class	Atypical dopamine reuptake inhibitor
Identifiers
IUPAC name 5-(3-bromophenyl)-phenylmethyl sulfinylmethyl-1,3-thiazole
CAS Number	2621388-55-2 Y
PubChem CID	156150588
Chemical and physical data
Formula	C17H14BrNOS2
Molar mass	392.33 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1=CC=C(C=C1)C(C2=CC(=CC=C2)Br)S(=O)CC3=CN=CS3
InChI InChI=1S/C17H14BrNOS2/c18-15-8-4-7-14(9-15)17(13-5-2-1-3-6-13)22(20)11-16-10-19-12-21-16/h1-10,12,17H,11H2 Key:KWWHBBCVAQTAFQ-UHFFFAOYSA-N

CE-158 is a highly selective DRI with much greater potency than modafinil.^[3][5] As (S,S)-CE-158, its inhibitory potencies (IC₅₀Tooltip half-maximal inhibitory concentration) at the monoamine transporters are 227 nM at the dopamine transporter (DAT), 11,970 nM at the norepinephrine transporter (NET) (53-fold lower), and inactive at the serotonin transporter (SERT).^[5]

The drug shows pro-motivational effects in animals and reverses tetrabenazine-induced motivational deficits.^[1] It increases dopamine levels in the nucleus accumbens, blocks amphetamine-induced dopamine release in vitro, shows no effect on locomotor activity with acute or repeated administration except at a high dose, and enhances learning in animals.^[3][2][5]

CE-158 was first described by 2020.^[5] It is closely related to CE-123, an earlier modafinil analogue.^[4][5] CE-158 and related agents are of interest in the potential treatment of motivational disorders, psychostimulant use disorder (PSUD), and Alzheimer's disease.^{[1][2][3][4][5]}

See also

• List of modafinil analogues and derivatives
• MRZ-9547
• PRX-14040